Related Experiment Video

Updated: Dec 31, 2025

Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR
07:24

Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR

Published on: April 8, 2013

24.7K

The Influence of Liraglutide for Heart Failure: A Meta-Analysis of Randomized Controlled Trials

Yu Zhang1, Qingmei Chen1, Guangyin Huang1

  • 1Department of Cardiology, Jiangjin District Central Hospital, Chongqing, China.

The Heart Surgery Forum
|January 3, 2020
PubMed

Insights

Liraglutide effectively reduces NT-proBNP and improves the 6-minute walk test (6MWT) in heart failure patients. However, it does not significantly impact cardiac function or reduce adverse cardiovascular events.

Area of Science:

  • Cardiology
  • Pharmacology
  • Clinical Trials

Background:

  • The role of liraglutide in managing heart failure is debated.
  • Existing research provides conflicting evidence on its clinical benefits.

Purpose of the Study:

  • To systematically review and meta-analyze randomized controlled trials (RCTs) evaluating liraglutide's effects on heart failure.
  • To clarify the influence of liraglutide on cardiac function and clinical outcomes in heart failure.

Main Methods:

  • A comprehensive search of major biomedical databases (PubMed, EMbase, Web of Science, EBSCO, Cochrane) was conducted up to March 2018.
  • Four RCTs involving 629 patients were included in a random-effects model meta-analysis.

Main Results:

  • Liraglutide significantly reduced NT-proBNP levels (Std. MD = -3.06) and improved the 6-minute walk test (6MWT) (Std. MD = 1.10).
  • No significant improvements were observed in left ventricular ejection fraction (LVEF), end-diastolic volume (LVEDV), or end-systolic volume (LVESV).
  • Liraglutide did not significantly reduce hospitalizations for heart failure, major adverse cardiovascular events, or cardiac death.

Conclusions:

  • Liraglutide demonstrates a beneficial effect in reducing NT-proBNP and enhancing exercise capacity (6MWT) in heart failure.
  • Current evidence suggests liraglutide does not significantly alter key cardiac structural/functional parameters or reduce major adverse cardiovascular events in this population.
Abstract

More Related Videos

Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution04:14

Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution

Published on: April 16, 2019

12.5K
Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction09:20

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction

Published on: February 13, 2021

6.9K

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
846
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
175
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.1K
Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
252
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
702
Heart Failure III: Clinical Manifestations01:26

Heart Failure III: Clinical Manifestations

Heart failure (HF) manifests primarily as dyspnea, fatigue, and fluid retention, resulting in peripheral and pulmonary edema. Symptoms may vary depending on which ventricle is more affected, left or right.Left-Sided Heart FailureAlso known as left ventricular failure, this condition results from the left ventricle's inability to fill or eject sufficient blood into the systemic circulation. It leads to pulmonary congestion, which occurs when the left ventricle fails to eject blood effectively...
391